EMR vs INTC Stock Comparison
Emerson Electric Co. vs Intel Corp.
EMR leads
EMR leads by 17 AIQ points, primarily on Risk Resilience and Value.
Competitive: 4 of 6 evidence groups support EMR, and its current signal state is conflicted.
Emerson Electric Co.
Intel Corp.
The Algovestiq AIQ Score currently favors EMR over INTC, 50 versus 33 as of Sep 5, 2026. EMR's advantage is driven primarily by stronger risk resilience and value. EMR also shows the stronger technical structure relative to its 50-day moving average. 4 of 6 covered evidence groups favor EMR today, and the comparison is rated Competitive on stability: the leader is throwing conflicting signals. EMR lead: Stable — the AIQ differential has held near 17 points over 30 sessions. EMR leads on all four AIQ factor dimensions. Value is itself one of those four, so a sweep is not explained by valuation alone — it deserves additional scrutiny for unmodeled catalysts, expectations or event risk.
Compare Emerson Electric Co. and Intel Corp. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Compare EMR and INTC against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Risk Resilience15%55 vs 30EMR +25
- Value30%49 vs 30EMR +19
- Quality30%56 vs 39EMR +17
- Momentum25%39 vs 33EMR +6
4 of 6 evidence groups favor EMR. EMR’s edge is concentrated in risk resilience and value.
What changed since the last close
Latest scored session 2026-09-04, compared against the prior scored session 2026-09-03.
No factor moved materially.
No new signals fired.
No factor moved materially.
No new signals fired.
EMR's lead was unchanged in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — EMR and INTC both carry a full feed there.
The central trade-off
EMR (Emerson Electric Co.): the stronger current systematic profile, led by risk resilience and value.
INTC (Intel Corp.): the counter-case, on technicals — but at materially higher volatility, 45.1% against 26.1%.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
EMREMR on the overall AIQ Score, which weights Quality and Value at 30% each.
Growth
EMREMR on combined revenue and EPS growth.
Value
EMREMR on the peer-relative Value factor, by 19 points.
Momentum
EMREMR on the Momentum factor, by 6 points.
Lower downside
EMREMR on Risk Resilience, by 25 points.
Analyst upside
EvenAnalyst targets are level or not covered for both names.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | EMR | INTC | Note |
|---|---|---|---|
| Implied upside to target | +7% | +7.6% | Level |
| Target dispersion | +31.2% | +135.8% | Lower is tighter analyst agreement |
| Consensus | Buy | Hold | Context, not a primary driver |
| Analysts covering | 9 | 27 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
4 of 6 covered evidence groups favor EMR. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | EMR | 50 vs 33 |
| Fundamentals | EMRon balance | revenue growth 6.8% vs 18.8%; EPS growth 16.4% vs -195.9%; TTM ROE 12.7% vs -10.8%; gross margin 53.2% vs 38.9% — EMR takes 3 of 4 decided legs, not all of them |
| Valuation | EMR | Value 49 vs 30 |
| Technicals | INTC | Price vs 50-day 2.4% vs -5.5%; vs 200-day 5.4% vs 24.1% |
| Risk Resilience | EMR | Risk Resilience 55 vs 30 |
| Analyst expectations | Even | Target upside 7% vs 7.6% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of EMR and INTC and are excluded from the count.
AIQ Decision Stability
The two are close enough that your objective, not the score, should decide.
- The AIQ gap is wide at 17 points. (supports the conclusion holding)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on EMR.
How the comparison changed
120 daily snapshots · Apr 23 – Sep 4EMR lead: Stable — the AIQ differential has held near 17 points over 30 sessions.
- Today
- EMR +17
- 50 vs 33
- 7 sessions ago
- EMR +18
- 52 vs 34
- 30 sessions ago
- EMR +18
- 59 vs 41
- 90 sessions ago
- EMR +9
- 51 vs 42
The lead changed hands 4 times in this window, most recently on May 5 when EMR moved ahead of INTC.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
3 bullish / 1 bearish, conflicted
- Golden Cross Active — bullish, trend, long horizon (4.70%)
- RSI Oversold - Potential Bounce — bullish, momentum, short horizon
- Uptrend Structure Active — bullish, trend, long horizon
2 bullish / 0 bearish / 1 neutral
- Golden Cross Active — bullish, trend, long horizon (37.24%)
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (5.65%)
- MACD Bullish Crossover — bullish, momentum, short horizon
EMR leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.74%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +4.51%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1INTC closes the Risk Resilience gap — currently 25 points behind, the largest single contributor to EMR's edge.
- 2INTC's ATR Expansion - Breakout Mode turns directional — it is neutral today and would confirm a change in trend.
- 3EMR's conflicting signal state resolves bearish — it currently carries 3 bullish and 1 bearish rules at once.
- 4A regime shift changes factor weighting — the composite weights Quality and Value at 30% each, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
EMR leads on balance| Metric | EMR | INTC |
|---|---|---|
| Revenue growth (YoY) | 6.8% | 18.8% |
| EPS growth (YoY) | 16.4% | -195.9% |
| Gross margin | 53.2% | 38.9% |
| Operating margin | 20.1% | 0.1% |
| Return on equity (TTM) | 12.7% | -10.8% |
| Debt to equity | 0.68 | 0.58 |
Performance
INTC leads 4 of 6 windows| Metric | EMR | INTC |
|---|---|---|
| 1 week (5 sessions) | -4.8% | -0.5% |
| 1 month (20 sessions) | -4.3% | -8.2% |
| 3 months (63 sessions) | 5.7% | -18% |
| 6 months (126 sessions) | 5.6% | 99.5% |
| Year to date | 13.2% | 148.4% |
| 1 year (252 sessions) | 14.3% | 278.6% |
Technicals
INTC has the stronger structure| Metric | EMR | INTC |
|---|---|---|
| RSI (14) | 28.7 | 30.6 |
| ADX (14) | 24.6 | 15.1 |
| Price vs 50-day | 2.4% | -5.5% |
| Price vs 200-day | 5.4% | 24.1% |
| Volatility (1M, annualized) | 26.1% | 45.1% |
Risk
EMR is the more resilient| Metric | EMR | INTC |
|---|---|---|
| Beta | 1.58 | 2.93 |
| Sharpe ratio | 0.5 | 2.04 |
| Sortino ratio | 0.76 | 3.79 |
| Max drawdown | -23.7% | -41.9% |
| Current drawdown | -8.6% | -35% |
| Annualized volatility | 32.3% | 79.1% |
| Value at risk (95%) | -3.5% | -6.2% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, EMR or INTC?
On the Algovestiq AIQ Score, EMR is the stronger of the two as of Sep 5, 2026, scoring 50 against INTC's 33. The edge comes from risk resilience and value. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is EMR or INTC the better buy right now?
EMR carries the stronger systematic profile as of Sep 5, 2026, and the comparison is rated Competitive — 4 of 6 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.
Why does the AIQ Score favor EMR over INTC?
The composite weights Quality at 30%, Value at 30%, Momentum at 25% and Risk Resilience at 15%. EMR leads Risk Resilience by 25 points; EMR leads Value by 19 points; EMR leads Quality by 17 points. EMR leads on all four AIQ factor dimensions. Value is itself one of those four, so the sweep is not explained by INTC simply being cheaper — it warrants extra scrutiny for unmodeled catalysts, forward expectations or event risk the factors do not capture.
Which has more analyst upside, EMR or INTC?
Analyst price targets imply +7% upside for EMR and +7.6% for INTC. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, EMR or INTC?
EMR is the better-valued of the two on the peer-relative Value factor. EMR on the peer-relative Value factor, by 19 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, EMR or INTC?
EMR on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, EMR or INTC?
EMR on the Momentum factor, by 6 points. Momentum carries 25% of the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, EMR or INTC?
EMR is the more resilient of the two, so the other name carries the higher downside risk. EMR on Risk Resilience, by 25 points. The Risk Resilience factor weights 15% of the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is EMR more profitable than INTC?
EMR leads on the comparable margin measures — gross margin 53.2% vs 38.9%; operating margin 20.1% vs 0.1%; ttm roe 12.7% vs -10.8%.
Is EMR's lead over INTC getting stronger or weaker?
EMR lead: Stable — the AIQ differential has held near 17 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-04-23 and 2026-09-04. The lead has changed hands 4 times in that window, most recently on 2026-05-05, when EMR moved ahead of INTC.
What would change the EMR vs INTC verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: INTC closes the Risk Resilience gap — currently 25 points behind, the largest single contributor to EMR's edge; INTC's ATR Expansion - Breakout Mode turns directional — it is neutral today and would confirm a change in trend; EMR's conflicting signal state resolves bearish — it currently carries 3 bullish and 1 bearish rules at once; a regime shift changes factor weighting — the composite weights Quality and Value at 30% each, so a rotation toward either would move the result most.
What do the current signals say about EMR and INTC?
EMR: 3 bullish / 1 bearish, conflicted. INTC: 2 bullish / 0 bearish / 1 neutral. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on EMR is Golden Cross Active (bullish, long horizon). On INTC it is Golden Cross Active (bullish, long horizon).
Compare EMR and INTC with others
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality (30%), Value (30%), Momentum (25%) and Risk (15%). Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.